Xencor, Inc.
XNCR Real Time Price USDRecent trades of XNCR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in XNCR holdings by institutional investors
Quarterly net insider trading by XNCR's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
XNCR Estimated quarterly lobbying spending
XNCR Revenue by Segment or Geography
New XNCR patent grants
-
Patent Title: Methods and compositions for inhibiting cd32b expressing cells Mar. 13, 2018
-
Patent Title: Methods and compositions for inhibiting cd32b expressing cells Feb. 27, 2018
-
Patent Title: Heterodimeric antibodies to cd3 x cd123 Jan. 02, 2018
-
Patent Title: Heterodimeric antibodies to cd3 x cd20 Dec. 26, 2017
-
Patent Title: Bispecific antibodies that bind to cd38 and cd3 Nov. 21, 2017
-
Patent Title: Fc variants with altered binding to fcrn Oct. 31, 2017
-
Patent Title: Optimized antibodies that target cd19 Oct. 31, 2017
-
Patent Title: Rapid clearance of antigen complexes using novel antibodies Aug. 22, 2017
-
Patent Title: Optimized fc variants and methods for their generation Jul. 25, 2017
-
Patent Title: Heterodimeric proteins Jul. 11, 2017
-
Patent Title: Optimized fc variants May. 30, 2017
-
Patent Title: Optimized fc variants May. 23, 2017
-
Patent Title: Heterodimeric proteins May. 16, 2017
-
Patent Title: Compositions and methods for treating ige-mediated disorders Apr. 11, 2017
-
Patent Title: Heterodimeric proteins Mar. 28, 2017
-
Patent Title: Antibodies with modified isoelectric points Mar. 28, 2017
-
Patent Title: Optimized anti-cd30 antibodies Feb. 21, 2017
-
Patent Title: Compositions and methods for treating ige-mediated disorders Jan. 10, 2017
-
Patent Title: Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens Nov. 15, 2016
-
Patent Title: Antibody variants with enhanced complement activity Oct. 25, 2016
-
Patent Title: Methods and compositions for inhibiting cd32b expressing cells Jul. 19, 2016
-
Patent Title: Ctla4-ig immunoadhesins Jun. 21, 2016
-
Patent Title: Optimized fc variants and methods for their generation May. 31, 2016
-
Patent Title: Compositions and methods for treating ige-mediated disorders Feb. 23, 2016
-
Patent Title: Methods and compositions for inhibiting cd32b expressing cells Feb. 16, 2016
-
Patent Title: Compositions and methods for treating ige-mediated disorders Dec. 29, 2015
-
Patent Title: Fc variants with altered binding to fcrn Dec. 01, 2015
-
Patent Title: Optimized fc variants and methods for their generation Nov. 24, 2015
-
Patent Title: Methods and compositions for inhibiting cd32b expressing cells Jul. 14, 2015
-
Patent Title: Compositions and methods for treating ige-mediated disorders Jun. 23, 2015
-
Patent Title: Optimized fc variants Jun. 09, 2015
-
Patent Title: Optimized antibodies that target hm1.24 May. 26, 2015
-
Patent Title: Modified fc molecules May. 26, 2015
-
Patent Title: Fc variants with increased affinity for fcγriic Jan. 20, 2015
-
Patent Title: Fc variants with altered binding to fcrn Nov. 11, 2014
-
Patent Title: Immunoglobulins insertions, deletions, and substitutions Nov. 11, 2014
-
Patent Title: Optimized fc variants and methods for their generation Oct. 14, 2014
-
Patent Title: Fc variants with altered binding to fcrn Oct. 07, 2014
-
Patent Title: Optimized fc variants and methods for their generation Aug. 19, 2014
-
Patent Title: Optimized fc variants Aug. 12, 2014
-
Patent Title: Fc variants with altered binding to fcrn Aug. 12, 2014
-
Patent Title: Optimized fc variants Jun. 17, 2014
-
Patent Title: Optimized fc variants Jun. 17, 2014
-
Patent Title: Optimized fc variants May. 27, 2014
-
Patent Title: Fc variants having increased affinity for fcyrllc May. 27, 2014
-
Patent Title: Optimized fc variants and methods for their generation May. 27, 2014
-
Patent Title: Antibodies with modified isoelectric points Jan. 28, 2014
-
Patent Title: Ctla4-ig immunoadhesins Jan. 14, 2014
-
Patent Title: Anti-cd40 antibodies and methods of inhibiting proliferation of cd40 expressing cells Oct. 08, 2013
-
Patent Title: Fc variants that extend antibody half-life Oct. 01, 2013
Federal grants, loans, and purchases
Estimated quarterly amount awarded to XNCR from public contracts
Recent insights relating to XNCR
Recent picks made for XNCR stock on CNBC
ETFs with the largest estimated holdings in XNCR
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $XNCR stock a Buy, Sell, or Hold?
- What is the price target for $XNCR stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $XNCR stock?
- Who owns the most shares of $XNCR stock?
- What funds own $XNCR stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view XNCR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
- Address Pasadena, CA
- Market Cap 1.2 billion
- Employees 250
- Industrial Classification Pharmaceutical Preparations